Compare VOC & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VOC | COCH |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Oil & Gas Production | Blank Checks |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 47.1M |
| IPO Year | N/A | N/A |
| Metric | VOC | COCH |
|---|---|---|
| Price | $3.19 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 126.4K | ★ 289.7K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $0.36 |
| 52 Week High | $3.84 | $1.91 |
| Indicator | VOC | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 45.92 |
| Support Level | $2.72 | $0.64 |
| Resistance Level | $3.37 | $0.88 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 3.79 | 35.49 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.